SEED HEALTH
THE EVOLUTION OF PROBIOTICS.
CAUSES
DELIVER GOOD HEALTH
DEAL DATE
APRIL 2021 (SERIES A)
CHECK SIZE
32.5M USD
INITIATIVES AND IMPACT
Founded in 2017 by Ara Katz and Raja Dhir, Seed Health is a microbial sciences company pioneering applications of microbes for human and planetary health. In collaboration with leading academic partners, they accelerate breakthrough science into live biotherapeutics and innovations for consumer health. All consumer innovations in probiotics are commercialized under Seed®.
At time of writing Seed’s flagship product is DS-01™, a 24 strain broad spectrum probiotic, recently received IND authorization for a clinical trial in IBS patients with Dr. Anthony Lembo at Harvard Medical School. It is also under study in four additional clinical trials to evaluate efficacy in endpoints related to constipation, post-alcohol gut microbiota restoration, urolithin production, and recovery after broad-spectrum antibiotics.
DELIVERING GOOD HEALTH
Seed Health develops probiotics designed to positively impact human and planetary health. “Advances in research reveal the vast potential of microbes to transform how we live and care for ourselves, our children and our environment. We are inspired to steward this next generation of probiotics and microbiome-based innovations that will disrupt and forever change the global categories of health, hygiene, diet and self-care.” said Ara Katz, Seed Health co-founder and co-CEO.
OPERATING AT THE LEADING EDGE OF PROBIOTICS
“We are converging advances in sequencing technologies, metabolomics, and functional strain characterization to gain insight into microbial communities and develop interventions that are effective across a heterogeneous population or personalized,” said Raja Dhir, Seed Health co-founder and co-CEO. “These proceeds accelerate our multi-platform, multi-technology approach to efficiently take breakthrough research from discovery to market across ecosystems of the body at various life stages, developmental windows, and health conditions.”
"SEED ACCELERATE BREAKTHROUGH SCIENCE INTO LIVE BIOTHERAPEUTICS AND INNOVATIONS FOR CONSUMER HEALTH."
THE DEAL
$40 MILLION IN SERIES A
This funding will support the company’s rapid growth and power upcoming category launches, clinical research, digital health initiatives, microbial stabilization technologies, and international expansion.
ERNESTO SCHMITT, CO-FOUNDER OF THE CRAFTORY SAID:
We are inspired to support Seed Health’s bold vision to realize the potential of microbes to impact health, sustain life on our planet and revolutionize how we live. Their commitment to rigor and transparency goes beyond exceptional science and probiotic innovation. They have quickly become industry leaders in their field and stewards of a new standard in science communication and global brand-building in consumer health. Their education and sustainability-first ethos reflects our mission to invest in challenger companies and founders with conviction.
2021 INNOVATION
The company’s first live biotherapeutic will enter FDA and EMA (European Medicines Agency) trials this year for recurrent Urinary Tract Infection (UTI) with renowned vaginal microbiome researcher, Dr. Jacques Ravel, in partnership with LUCA Biologics.
